AI Engines For more Details: Perplexity Kagi Labs You
Cancer Risk: One of the most significant long-term health impacts of diethylstilbestrol exposure is an increased risk of certain cancers. Women who were exposed to DES in utero have a higher risk of developing clear cell adenocarcinoma of the vagina or cervix, as well as an increased risk of breast cancer. Additionally, DES-exposed individuals may have an elevated risk of certain reproductive cancers, such as ovarian cancer.
Reproductive Disorders: DES exposure in utero has been associated with various reproductive tract abnormalities in both males and females. In females, these may include structural abnormalities of the uterus, cervix, and fallopian tubes, as well as an increased risk of infertility, miscarriage, and preterm birth. In males, DES exposure may lead to genital abnormalities such as undescended testicles, hypospadias (urethral opening on the underside of the penis), and reduced sperm count.
Hormonal Effects: DES is an estrogenic compound, and exposure to high levels of estrogen during fetal development can disrupt normal hormonal balance and development. This can lead to various hormonal effects and imbalances in both males and females, potentially affecting reproductive function, sexual development, and other physiological processes regulated by hormones.
Risk of Adverse Pregnancy Outcomes: Women who were exposed to DES in utero may have an increased risk of adverse pregnancy outcomes, such as ectopic pregnancy, miscarriage, preterm birth, and stillbirth. Additionally, DES-exposed women may be more likely to require interventions such as cesarean section or assisted reproductive technologies to achieve pregnancy.
Psychological and Emotional Impact: The knowledge of being exposed to DES in utero and the potential health risks associated with it can have psychological and emotional impacts on affected individuals and their families. This may include anxiety, stress, depression, and concerns about reproductive health and cancer risk.
Health Monitoring: Given the long-term health risks associated with DES exposure, individuals who were exposed to DES in utero or their offspring may require regular health monitoring and screening for cancer and other health conditions. Healthcare providers may recommend specific screening tests and surveillance measures based on individual risk factors and medical history.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
Acne | 0.4 | -0.4 | |
ADHD | 5.8 | 0.7 | 7.29 |
Age-Related Macular Degeneration and Glaucoma | 0.9 | 0.5 | 0.8 |
Allergic Rhinitis (Hay Fever) | 2.4 | 1.8 | 0.33 |
Allergies | 5.2 | 4.2 | 0.24 |
Allergy to milk products | 1.8 | 1 | 0.8 |
Alopecia (Hair Loss) | 2.1 | 2.1 | |
Alzheimer's disease | 5.3 | 6 | -0.13 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.2 | 1.7 | 1.47 |
Ankylosing spondylitis | 4.4 | 2.1 | 1.1 |
Anorexia Nervosa | 0.5 | 2.8 | -4.6 |
Antiphospholipid syndrome (APS) | 2.8 | 0.2 | 13 |
Asthma | 1.3 | 2.4 | -0.85 |
Atherosclerosis | 1.4 | 3.4 | -1.43 |
Atrial fibrillation | 4 | 2.7 | 0.48 |
Autism | 11.7 | 10.8 | 0.08 |
Barrett esophagus cancer | 0.5 | 0.4 | 0.25 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 1.7 | 1.6 | 0.06 |
Brain Trauma | 0.6 | 1 | -0.67 |
Carcinoma | 4.4 | 3.4 | 0.29 |
Celiac Disease | 2.1 | 4.3 | -1.05 |
Cerebral Palsy | 1.8 | 1.9 | -0.06 |
Chronic Fatigue Syndrome | 5.3 | 8.1 | -0.53 |
Chronic Kidney Disease | 2.4 | 2 | 0.2 |
Chronic Lyme | 1 | -1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 2.7 | 1 | 1.7 |
Chronic Urticaria (Hives) | 1.5 | 2.9 | -0.93 |
Coagulation / Micro clot triggering bacteria | 1.5 | 1.9 | -0.27 |
Colorectal Cancer | 6.6 | 1 | 5.6 |
Constipation | 1 | 1 | 0 |
Coronary artery disease | 1.8 | 1 | 0.8 |
COVID-19 | 13.5 | 17.9 | -0.33 |
Crohn's Disease | 9.6 | 7 | 0.37 |
cystic fibrosis | 0.5 | 1.3 | -1.6 |
deep vein thrombosis | 0.5 | 1.4 | -1.8 |
Depression | 11.7 | 10.3 | 0.14 |
Dermatomyositis | 0.4 | 0.4 | 0 |
Eczema | 1 | 3.3 | -2.3 |
Endometriosis | 3.7 | 1 | 2.7 |
Eosinophilic Esophagitis | 0.4 | 0 | 0 |
Epilepsy | 4.1 | 4.2 | -0.02 |
Fibromyalgia | 3.6 | 3.6 | 0 |
Functional constipation / chronic idiopathic constipation | 6.6 | 5.6 | 0.18 |
gallstone disease (gsd) | 2.5 | 1.3 | 0.92 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.8 | 1.4 | 0.29 |
Generalized anxiety disorder | 2.2 | 2.3 | -0.05 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.4 | -0.4 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 1.6 | 1.6 | 0 |
Halitosis | 1 | 0.4 | 1.5 |
Hashimoto's thyroiditis | 2.9 | 1 | 1.9 |
Hidradenitis Suppurativa | 1 | 0 | 0 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 3.7 | 1.1 | 2.36 |
hypercholesterolemia (High Cholesterol) | 1 | 0.9 | 0.11 |
hyperglycemia | 0.2 | 3.2 | -15 |
Hyperlipidemia (High Blood Fats) | 1 | 0.2 | 4 |
hypersomnia | 0.7 | -0.7 | |
hypertension (High Blood Pressure | 3.1 | 5.9 | -0.9 |
Hypothyroidism | 1.6 | -1.6 | |
Hypoxia | 1.5 | 1.5 | |
IgA nephropathy (IgAN) | 4.9 | -4.9 | |
Inflammatory Bowel Disease | 5.3 | 11.6 | -1.19 |
Insomnia | 1.4 | 1 | 0.4 |
Intelligence | 1.3 | 1 | 0.3 |
Intracranial aneurysms | 1.9 | 0.2 | 8.5 |
Irritable Bowel Syndrome | 5.7 | 4.4 | 0.3 |
Liver Cirrhosis | 6.3 | 4.2 | 0.5 |
Long COVID | 9.2 | 10 | -0.09 |
Low bone mineral density | 1 | -1 | |
Lung Cancer | 1.2 | 2.2 | -0.83 |
ME/CFS with IBS | 1.1 | 3.5 | -2.18 |
ME/CFS without IBS | 2.5 | 2.9 | -0.16 |
Menopause | 2.4 | 2.4 | |
Metabolic Syndrome | 10.3 | 10.2 | 0.01 |
Mood Disorders | 15 | 10.5 | 0.43 |
multiple chemical sensitivity [MCS] | 1.9 | 0.5 | 2.8 |
Multiple Sclerosis | 7.5 | 7.6 | -0.01 |
Multiple system atrophy (MSA) | 2.2 | 1.3 | 0.69 |
Neuropathy (all types) | 1.4 | 0.2 | 6 |
neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.2 | 6.9 | -1.16 |
NonCeliac Gluten Sensitivity | 0.4 | -0.4 | |
Obesity | 9.7 | 6.8 | 0.43 |
obsessive-compulsive disorder | 7.4 | 6 | 0.23 |
Osteoarthritis | 2.7 | 0.4 | 5.75 |
Osteoporosis | 1.8 | 1.9 | -0.06 |
pancreatic cancer | 0.9 | 0.9 | |
Parkinson's Disease | 4.1 | 5.4 | -0.32 |
Polycystic ovary syndrome | 2.9 | 3.1 | -0.07 |
Postural orthostatic tachycardia syndrome | 0.5 | 0.8 | -0.6 |
Premenstrual dysphoric disorder | 1.1 | 0.5 | 1.2 |
primary biliary cholangitis | 0.4 | 0.5 | -0.25 |
Psoriasis | 5.2 | 4.9 | 0.06 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.4 | 4.9 | 0.71 |
Rosacea | 1 | 1 | 0 |
Schizophrenia | 7.5 | 2.7 | 1.78 |
scoliosis | 0.5 | 0.6 | -0.2 |
Sjögren syndrome | 3.2 | 3.8 | -0.19 |
Sleep Apnea | 2.2 | 2.2 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 0.5 | 1.4 |
Stress / posttraumatic stress disorder | 4 | 3.4 | 0.18 |
Systemic Lupus Erythematosus | 5.7 | 2.3 | 1.48 |
Tic Disorder | 1.2 | 2.1 | -0.75 |
Tourette syndrome | 0.5 | 0.5 | 0 |
Type 1 Diabetes | 4.6 | 2.7 | 0.7 |
Type 2 Diabetes | 10.1 | 9.5 | 0.06 |
Ulcerative colitis | 3.3 | 7.4 | -1.24 |
Unhealthy Ageing | 6.6 | 3.1 | 1.13 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.